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Abstract
Background: Multiple drug-resistance in new tuberculosis (TB) cases accounts for the majority of all multiple drug-resistant
TB (MDR-TB) worldwide. Effective control requires determining which new TB patients should be tested for MDR disease, yet
the effectiveness of global screening recommendations of high-risk groups is unknown.
Methods: Sixty MDR-TB cases with no history of previous TB treatment, 80 drug-sensitive TB and 80 community-based
controls were recruited in Lima, Peru between August and December, 2008 to investigate whether recommended screening
practices identify individuals presenting with MDR-TB. Odd ratios (OR) and 95% confidence intervals (CI) were calculated
using logistic regression to study the association of potential risk factors with case/control variables.
Results: MDR-TB cases did not differ from drug-sensitive TB and community controls in rates of human immunodeficiency
virus infection, reported hospital or prison visits in the 3 years prior to diagnosis. MDR-TB cases were more likely than drug-
sensitive TB controls to have had a recent MDR-TB household contact (OR 4.66, (95% CI 1.56–13.87)); however, only 15 cases
(28.3%) reported this exposure. In multivariate modeling, recent TB household contact, but not contact with an MDR-TB
case, remained predictive of MDR-TB, OR 7.47, (95% CI 1.91–29.3). Living with a partner rather than parents was associated
with a lower risk of MDR-TB, OR 0.15, (95% CI 0.04–0.51).
Conclusion: Targeted drug susceptibility testing (DST) linked to reported MDR-TB contact or other high-risk exposures does
not identify the majority of new TB cases with MDR disease in Lima where it is endemic. All new TB cases should be
screened with DST to identify MDR patients. These findings are likely applicable to other regions with endemic MDR-TB.
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Introduction
Multiple drug-resistant tuberculosis (MDR-TB) is growing world-
wide, and threatens to undermine global tuberculosis (TB) control
efforts. [1] In 2008 there were an estimated 440,000 incident MDR-
TB cases globally; among those tested, 5.4% of MDR-TB patients had
extensively drug-resistant (XDR)-TB. [2,3] Inappropriate or inade-
quate TB treatment programs are assumed to be responsible for
generating MDR disease, and TB patients with a history of previous
treatment are as much as 10 times more likely to have MDR disease
than those without previous TB therapy. [4,5] Despite the well-
documented association between previous TB treatment and MDR
disease, transmission of MDR-TB, instead of inadequate or inappro-
priate therapy, is responsible for the majority of cases worldwide. [6]
Even excellent national TB control programs (NTP) based on
the Directly-Observed Therapy, Short-course (DOTS) strategy
may experience substantial increases in MDR-TB, [6] and
observational and modeling studies suggest that DOTS treatment
expansion may preferentially select for drug-resistant TB trans-
mission in endemic locations. [7,8,9] TB incidence has declined
substantially in Peru since the introduction of its NTP in 1990;
however, MDR-TB cases grew 27-fold from 1997 to 2005. [10]
Understanding MDR-TB transmission is crucial to global TB
control efforts, yet little is known about MDR-TB risk factors in
new TB cases with either no history or ,1 month history of
previous TB therapy. [11,12]
Selected groups such as social, nosocomial or household
contacts of MDR-TB patients have been shown to be at high-
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control plans call for targeted screening of selected new TB
patients for MDR-TB prevention. [17] However, the percentage
of new TB patients with MDR disease likely to be identified by
targeted screening is unknown. If global MDR-TB control efforts
are to succeed, it is imperative to understand if recommended
screening strategies will identify most individuals at risk for MDR
disease in TB-endemic locations. We undertook a case-control
study to examine MDR-TB risk factors in new TB patients at a
well-run NTP in Peru.
Methods
Design
This study was a population based case-control study.
Recruitment
Cases and controls were recruited between August 1, 2008 and
December 12, 2008 in the San Juan de Lurigancho (SJL) district of
Lima, one of the poorest and most populated districts in Peru. In
2007 SJL accounted for 3.2% of the Peruvian population (898,443
inhabitants), but reported 7.0% (2,044/29,393) of all TB cases and
14.2% (116/818) of all MDR-TB cases. [18] Cases were identified
from an unrelated study of rapid diagnostics for MDR-TB in
consecutive new TB patients in SJL. All adult patients $18 years
old with laboratory proven MDR-TB, no history of previous TB
treatment and who were being followed in a SJL NTP clinic
during the recruitment period were eligible to be cases. Drug-
sensitive pulmonary TB controls were randomly selected in blocks
of 30 from a database of all TB patients followed in SJL NTP
clinics; medical records were reviewed to determine eligibility,
which included $18 years old, no history of previous TB
treatment, sputum smear-negative at 2 months on NTP standard
therapy and no treatment failure or relapse at the time of
interview. Because sputum cultures and drug susceptibility testing
(DST) are not routinely performed in the Peru NTP, response to
standard therapy within 2 months of initiating treatment was used
as a surrogate for drug-sensitive TB.
To select community controls, a population weighted sampling
method based on the 34 NTP clinic catchment areas was
developed. Catchment areas were randomly chosen using a
computer-generated scheme, where any given area might be
selected once, multiple times or not at all. Each chosen catchment
area was divided into subdivisions of approximately equal size, and
a computer-based random number generator was used to create a
list of subdivisions in SJL where the research nurse went to find
community controls. Upon arriving at the selected locations, the
first adult $18 year old encountered and who on questioning did
not have a history of prior TB was invited to participate in the
study. If that person refused or was not eligible, the interviewer
approached another person until someone agreed to participate
[19].
All study participants provided informed, written consent before
being enrolled. The study was reviewed and approved by the
Human Subjects Review Committees of Universidad Peruana
Cayetano Heredia (UPCH), the McGill University Health Centre
Research Institute and the Ministry of Health Direccio ´n de Salud
Lima Este.
Questionnaire design
Questionnaires were developed to explore reported demograph-
ic, socioeconomic and exposure factors associated with MDR-TB.
Primary hypotheses included investigating the role of reported
healthcare and prison visits before MDR-TB diagnosis and time
spent living in SJL where MDR-TB rates exceed much of Lima
and Peru. Risk factors associated with education, employment,
income, health and personal behaviors, housing conditions,
neighborhood characteristics, and transportation also were
studied.
Questionnaires were developed in English, translated into
Spanish by native Spanish speakers fluent in both languages and
then were back-translated by bilingual individuals not involved in
the original translations. Discrepancies were resolved by consen-
sus. The questionnaires were pilot tested in 10 UPCH employees
for comprehensibility, language level and length of time. After
adjustment, the questionnaires were field tested with 10 MDR-TB
patients, 10 TB controls and 10 community controls after
informed consent. These tests were used to make final adjustments
after which no further changes were made. Data from the 40 pilot
questionnaires were not used in the analyses. All questionnaires
were administered orally in Spanish by trained research nurses or
study investigators.
Statistical Analysis
With 60 MDR-TB cases and a similar number of controls, we
anticipated having 80% power to detect odd ratios (OR) of 3.0 or
more for risk factors prevalent in at least 15% of the population at
a significance level of 0.05. [20] These OR are in the range of
commonly reported TB risk factors. [5,11,21]
After simple descriptive analysis, the association of potential
risk factors with the case/control variables was studied using
logistic regression. We computed the crude and adjusted OR with
95% confidence intervals (CI). We used simple univariate logistic
regression for categorical and continuous variables to assess the
individual correlates of community controls, drug-sensitive TB
controls and MDR-TB cases. Multivariate analysis was conduct-
ed to fit a model for the dichotomous outcome comparing MDR-
TB cases with drug-sensitive TB controls. The adjustment was
performed at first by developing a ‘full’ logistic regression model,
which included all potential risk factors with crude OR significant
at the 10% level. In order to deal with multicollinearity,
backward-stepwise variable selection was performed to eliminate
redundant covariates. The final model reported was the one
minimizing the Bayesian Information Criterion (BIC). [22] The
Hosmer-Lemeshow test was used to assess the goodness-of-fit of
our final model (minimum BIC). All calculations were performed
using R software.
Role of the funding source
The study sponsors had no role in the study design,
implementation, data collection, analyses, interpretation or the
writing of this report. The authors had full access to all data and
final responsibility for the decision to submit this study for
publication.
Results
Sixty-five newly diagnosed TB patients with MDR disease were
followed in SJL NTP clinics during the study period; 60 (92.3%)
agreed to participate and were compared with 80 randomly
selected drug-sensitive TB controls and 80 community controls.
Eighty-two drug-sensitive pulmonary TB patients were ap-
proached to enroll 80 controls (97.6% participation rate). Among
community controls, 154 individuals were approached in order to
enroll 80 controls. Refusals—74 (48.1%)—had less education than
participants (p=0.0003); otherwise there were no significant
differences between community participants and non-participants
in terms of age, gender or civil status.
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and community controls from Lima, Peru, August-December 2008.
Community
Controls
Number
(%) (n=80)
DS-TB
Controls
Number
(%) (n=80)
MDR-TB
Cases
Number
(%) (n=60)
MDR compared with
pooled controls, Odds
Ratio (95%
Confidence Intervals) p values
Age in years, mean [s.d.] 38.6 [13.5] 33.6 [15.3] 29.9 [12.1] 0.97 (0.94–0.99) 0.0070
Sex
Male 42 (52.5) 45 (56.3) 30 (50.0) Ref
Female 38 (47.5) 35 (43.8) 30 (50.0) 1.19 (0.66–2.16) 0.5625
Civil status
Co-habiting/Married 50 (62.5) 41 (51.3) 17 (28.3) Ref
Single 25 (31.3) 29 (36.3) 38 (63.3) 3.77 (1.94–7.32) ,0.0001
Separated/Widowed 5 (6.3) 10 (12.5) 5 (8.3) 1.78 (0.57–5.56) 0.3182
Ethnic group
Mestizo 72 (90.0) 63 (78.8) 52 (86.7) Ref
White 2 (2.5) 6 (7.5) 5 (8.3) 1.62 (0.51–5.19) 0.4144
Quechua 5 (6.2) 8 (10.0) 1 (1.7) 0.20 (0.03–1.57) 0.1252
Other 1 (1.2) 3 (3.7) 2 (3.3) 1.30 (0.23–7.31) 0.7672
Highest level of education
No schooling or Incomplete Primary 4 (5.0) 6 (7.5) 4 (6.7) Ref
Complete Primary or
Incomplete/Complete Secondary
57 (71.3) 59 (73.8) 36 (60.0) 0.78 (0.23–2.62) 0.6831
Technical or University 19 (23.8) 15 (28.7) 20 (33.3) 1.47 (0.41–5.31) 0.5560
Vaccinated with BCG *
No 2 (2.5) 10 (12.5) 9 (15.3) Ref
Yes 74 (92.5) 63 (78.8) 47 (79.7) 0.46 (0.18–1.15) 0.0977
Unsure 4 (5.0) 7 (8.8) 3 (5.1) 0.36 (0.078–1.70) 0.1984
Housing
Rent 17 (21.3) 15 (18.8) 8 (13.3) Ref
Own 26 (32.5) 30 (37.5) 23 (38.3) 1.64 (0.66–4.10) 0.2876
Lives with family or friends 37 (46.2) 35 (43.7) 29 (48.3) 1.61 (0.66–3.91) 0.2921
Length of time living in the district
,5 years 9 (11.2) 20 (25.0) 8 (13.3) Ref
6–10 years 8 (11.3) 9 (11.3) 10 (16.7) 2.13 (0.71-6.44) 0.1795
11–15 years 8 (10.0) 9 (11.3) 6 (10.0) 1.28 (0.38–4.32) 0.6914
.15 years 55 (68.7) 42 (52.5) 36 (60.0) 1.35 (0.56–3.22) 0.5047
Number of household members
at the time of diagnosis
0–2 15 (18.7) 22 (27.5) 10 (16.7) Ref
3–6 46 (57.5) 36 (45.0) 30 (50.0) 1.35 (0.60–3.06) 0.4663
.7 19 (23.7) 22 (27.5) 20 (33.3) 1.81 (0.75–4.35) 0.1884
Unemployed in the 12 months
prior to TB Diagnosis
47 (58.8) 38 (47.5) 30 (50.0) 0.88 (0.49–1.60) 0.6795
Monthly Household Income (soles) *
.600 49 (66.2) 36 (50.7) 26 (49.1) Ref
300–600 25 (33.8) 20 (28.2) 20 (37.7) 1.45 (0.73–2.89) 0.2856
,300 0 (0) 15 (21.1) 7 (13.2) 1.53 (0.56–4.14) 0.4072
Attended hospital in 3 years
prior to TB diagnosis
63 (78.7) 63 (78.7) 43 (71.7) 0.68 (0.31–1.48) 0.3334
HIV positive 0 (0.0) 3 (3.7) 0 (0.0) N/A N/A
Immunocompromised
1 9 (11.3) 14 (17.5) 13 (21.6) 1.65 (0.77–3.51) 0.1957
Depression 1 (1.3) 1 (1.3) 8 (13.3) 12.15 (2.50–59.04) 0.0020
Diabetes 0 (0.0) 3 (3.7) 4 (6.7) 3.74 (0.81–17.22) 0.0907
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in the number of reported health care center visits or
hospitalizations in the 3 years prior to TB diagnosis or interview
in the case of community controls, type of health care center
visited, length of time spent in waiting rooms, alcohol use, a history
of incarceration or prison visits, or length of time living in SJL
(Tables 1 and 2). Cases and controls did not report differences in
known exposures to neighbors with TB symptoms, TB disease or
who had died from TB; however, MDR-TB cases were more likely
to report knowing a neighbor who also had MDR-TB than drug-
sensitive TB or community controls (13.7% vs. 4.0% vs. 2.5%, p
for trend=0.0016). Eighteen percent of MDR-TB cases reported
a previous TB death in the household, compared with 7.6% of TB
controls and 1.3% of community controls (p for trend=0.0022).
There were no significant differences among MDR-TB cases
and drug-sensitive TB or community controls in reported
ethnicity, level of education, household income, illicit drug use
or reported history of Bacille Calmette-Gue ´rin vaccination. Only 3
TB controls (3.7%) were human immunodeficiency virus (HIV)
co-infected. Cases and controls did not differ in the percentage
with heart, lung or renal disease, other causes of immunosuppres-
sion or diabetes. MDR-TB cases were younger than drug-sensitive
TB or community controls (29.9 vs. 33.6 vs. 38.6 years,
p=0.0011), and were more likely to be single (Table 1).
In bivariate analyses drug-sensitive TB controls were more likely
than MDR-TB cases to live at home, to report a household
contact diagnosed with TB in the last 3 years or to report a
household contact with MDR-TB, yet only 15 cases (28.3%)
reported household contact with a previous MDR-TB patient.
Cases also were more likely to have worked indoors than drug-
sensitive TB controls. Having a household contact with TB
symptoms was borderline significant for MDR disease (Table 2).
In multivariate modeling comparing MDR-TB cases with drug-
sensitive TB controls, having a household member with a TB
diagnosis in the past three years remained predictive of MDR-TB,
odds ratio (OR) 7.47, (95% CI 1.91–29.3). Living with a partner
rather than parents was associated with a lower risk of MDR
disease, OR 0.15, (95% CI 0.04–0.51) (Table 3). The Hosmer-
Lemeshow test statistic to assess the goodness-of-fit of our final
model was 3.899 based on 8 degrees of freedom, which
corresponds to a p-value of 0.867, indicating a very good fit.
Discussion
Despite the expansion of DOTS control programs worldwide,
MDR-TB—particularly MDR disease in persons with no history
of previous TB treatment—is increasing. For targeted DST to be
an effective strategy for containing the growing MDR-TB
epidemic, it is imperative to determine whether self-reported risk
factors will identify new TB patients with MDR disease.
We describe one of the largest population-based case-control
studies to date of MDR-TB risk factors in new TB patients and
include community controls. Peru has a long-standing, compre-
hensive NTP that provides therapy to essentially all TB patients
while achieving WHO detection and treatment targets. [23] The
NTP case detection rate was 93% in 2007, and 92% of patients
were successfully treated; in contrast to some sub-Saharan African
countries, few TB patients are HIV co-infected. [18,24] Passive
case detection using sputum smears is done to screen patients for
TB. Sputum cultures are routinely performed only in HIV co-
infected individuals, healthcare workers, contacts of MDR-TB
patients, retreatment or smear-negative cases. Patients who remain
smear-positive after 2 months of NTP standard TB treatment also
are referred for sputum culture and DST. Newly presenting TB
patients who fail NTP standard therapy here are at high-risk for
having culture-positive MDR disease. [25,26]
Our results demonstrate that MDR-TB in new cases in this
setting are not easily distinguished from drug-sensitive TB patients
or community controls by self-reported socio-economic or
demographic factors or time spent in potentially high-risk settings
such as hospitals or prisons. MDR-TB cases were more likely than
drug-sensitive TB controls to report having had a recent
household contact with TB or MDR-TB; however, only 28.3%
of new cases with MDR disease reported exposure to a household
contact with MDR-TB. MDR-TB cases were younger than
controls, and were more likely to live at home. In multivariate
modeling, living with a partner remained protective against having
MDR-TB, OR 0.15, (95% CI 0.04–0.51). Detecting MDR disease
in this setting is time-consuming, usually requiring at least 3 to 6
months to make a diagnosis. [27] Delays in identifying and
treating MDR-TB in Lima could contribute to the observation
that these patients were more likely to live with family as their
extended illness may affect their ability to work or support
themselves independently. However, other possible explanations
for the association between MDR-TB disease and living at home,
such as younger age, exist. Additional study is needed to
understand the reason for this association.
These findings have important implications for TB control in
SJL and similar locations where MDR disease exists. First, they
suggest that MDR-TB in this population is an endemic disease,
not confined to outbreaks or special groups. Second, they suggest
Community
Controls
Number
(%) (n=80)
DS-TB
Controls
Number
(%) (n=80)
MDR-TB
Cases
Number
(%) (n=60)
MDR compared with
pooled controls, Odds
Ratio (95%
Confidence Intervals) p values
Lung disease 4 (5.0) 3 (3.8) 3 (5.0) 1.15 (0.29–4.60) 0.8430
Smoking status
Never 29 (36.3) 29 (36.3) 30 (50.0) Ref
Ex-smoker 19 (23.8) 49 (61.3) 29 (48.3) 0.83 (0.44–1.53) 0.5412
Current 32 (40.0) 2 (2.5) 1 (1.7) 0.057 (0.007–0.44) 0.0058
Drug use (illicit) 1(1.2) 12(15.0) 5(8.3) 1.028 (0.35–3.018) 0.9597
*Excludes missing values; N/A – not applicable;
1On steroids or diagnosed with another medical condition associated with immunodeficiency.
doi:10.1371/journal.pone.0025861.t001
Table 1. Cont.
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tuberculosis (DS-TB) controls from Lima, Peru, August-December, 2008.
DS-TB Controls,
n (%) (n=80)
MDR-TB Cases,
n (%) (n=60)
Odds Ratio (95%
Confidence Limit) p-values
In jail in 3 years prior to diagnosis 7 (8.8) 1 (1.7) 0.18 (0.021–1.48) 0.0740
Living at the time of diagnosis with:
Mother 26 (32.5) 33 (55.0) 2.54 (1.27–5.066) 0.0076
Father 17 (21.3) 27 (45.0) 3.032 (1.45–6.35) 0.0027
Grandparent 4 (5.0) 2 (3.3) 0.66 (0.12–3.70) 0.7003
Sibling 28 (35.0) 39 (65.0) 3.45 (1.71–6.96) 0.0004
Partner 39 (48.8) 15 (25.0) 0.35 (0.17–0.73) 0.0043
Shares a bedroom 55 (68.7) 42 (70.0) 1.061 (0.51–2.20) 0.8739
No. bedrooms in the house *
1–2 34 (43.0) 27 (45.0) Ref
3–4 30 (38.0) 19 (31.7) 0.80 (0.37–1.71) 0.5623
.5 15 (19.0) 14 (23.3) 1.18 (0.48–2.85) 0.7210
Household member in the 3 years
prior to TB diagnosis with:
TB Symptoms 21 (26.2) 25 (41.7) 2.009 (0.98–4.10) 0.0546
TB Diagnosis 13 (16.3) 23 (38.3) 3.20 (1.45–7.057) 0.0031
Anyone else who ever lived in
the same house with: **
TB Treatment
No 51 (69.9) 35 (58.3) Ref
Yes 22 (30.1) 25 (41.7) 1.66 (0.81–3.31) 0.1677
MDR-TB Diagnosis
No 59 (92.2) 38 (71.7) Ref
Yes 5 (7.8) 15 (28.3) 4.66 (1.56–13.87) 0.0057
Death from TB
No 70 (92.1) 48 (81.4) Ref
Yes 6 (7.9) 11 (18.6) 2.67 (0.93–7.72) 0.0691
Anyone in the neighborhood with: **
TB Symptoms
No 38 (63.3) 26 (55.3) Ref
Yes 22 (36.7) 21 (44.7) 1.40 (0.64–3.039) 0.4020
TB Diagnosis
No 39 (63.9) 25 (52.1) Ref
Yes 22 (36.1) 23 (47.9) 1.63 (0.76–3.52) 0.2135
MDR-TB Diagnosis
No 38 (92.7) 29 (80.6) Ref
Yes 3 (7.3) 7 (19.4) 3.057 (0.73–12.86) 0.1272
Death from TB
No 64 (97.0) 50 (92.6) Ref
Yes 2 (3.0) 4 (7.4) 2.56 (0.45–14.55) 0.2889
Anyone in the Workplace with: **
TB Symptoms
No 41 (68.3) 27 (58.7) Ref
Yes 19 (31.7) 19 (41.3) 1.51 (0.68–3.38) 0.3062
TB Diagnosis
No 45 (81.8) 25 (75.8) Ref
Yes 10 (22.2) 8 (24.2) 1.44 (0.50–4.12) 0.4963
MDR-TB Diagnosis
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only those presumed to be at high-risk for MDR-TB. Identifying
high-risk groups for selected DST is currently practiced in Peru
and recommended by global TB control plans. [1,17] While
potentially useful, [28] selected DST is unlikely to control MDR-
TB transmission in SJL. Existing recommendations for DST in
new TB patients would have missed almost three-quarters of all
new cases of MDR-TB in this district. Effective TB control in SJL
will likely at a minimum entail introducing routine DST for all
new patients with a history of recent TB contact. More likely
universal DST in new TB patients will be needed, a recommen-
dation applicable to other areas with similar high rates of MDR
disease such as Shanghai, China. [29]
The lack of timely diagnostic tests for MDR-TB leads to
substantial delays in the identification and treatment of MDR-TB
patients, and may contribute to MDR-TB transmission in
communities. [30] A number of diagnostic methods have been
developed which show promise in rapidly recognizing MDR-TB,
including microscopic-observation drug susceptibility assays
(MODS) and automated real-time polymerase-chain-reaction
based tests. [31,32] MODS uses inverted light microscopy to
observe characteristic cord formation of Mycobacterium tuberculosis
DS-TB Controls,
n (%) (n=80)
MDR-TB Cases,
n (%) (n=60)
Odds Ratio (95%
Confidence Limit) p-values
No 45 (97.8) 23 (88.5) Ref
Yes 1 (2.2) 3 (11.5) 5.87 (0.58–59.55) 0.1347
Death from TB
No 61 (98.4) 43 (95.5) Ref
Yes 1 (1.6) 2 (4.4) 2.84 (0.25–32.29) 0.4007
Workplace environment *
Exterior 28 (45.1) 15 (27.2) Ref
Interior 34 (54.8) 40 (72.2) 2.20 (1.011–4.72) 0.0470
Number of people working in the same room *
0 28 (45.2) 17 (30.9) Ref
1–4 16 (25.8) 14 (25.4) 1.44 (0.57–3.68) 0.4445
.5 18 (29.0) 24 (43.6) 2.20 (0.93–5.18) 0.0724
*Excludes missing values;
**Excludes unsure responses.
doi:10.1371/journal.pone.0025861.t002
Table 2. Cont.
Table 3. Multivariate comparison of exposure risk factors in multiple drug-resistant tuberculosis (MDR-TB) cases with drug-
sensitive tuberculosis (DS-TB) controls.
Univariate Analysis
Odds ratio (OR) (95%
confidence intervals)* Full Model OR (95% CI)
Best Bayesian
Information Criterion
Model OR (95% CI)
Living at the time of diagnosis with:
Mother 2.29 (0.99–5.27)
{ 0.07 (0.003–1.85)
Father 2.73 (1.14–6.52)
{ 3.89 (0.54–28.1)
Sibling 4.21 (1.77–10.04)
{ 15.4 (1.15–205)
{
Partner 0.25 (0.10–0.65)
{ 0.11 (0.01–0.97)
{ 0.15 (0.04–0.51)
{
Household member in the 3
years prior to TB diagnosis with:
TB Symptoms 2.27 (0.93–5.53)
{ 0.08 (0–12.63)
TB Diagnosis 4.37 (1.60–11.97)
{ 4.1 (0.3–18527) 7.47 (1.91–29.3)
{
Anyone else who ever lived
in the same house with:
1
TB Treatment 2.27 (0.93–5.53)
{ 0.024 (0–5.42)
MDR–TB Diagnosis 3.27 (0.92–11.55)
{ 9.96 (0.59–1672)
Death from TB 3.36 (0.81–13.93) 3.68 (0.041–333)
*Study participants with missing observations for variables retained in multivariate model were excluded.
1Excludes missing values or unsure responses.
{p#0.10;
{p#0.05.
doi:10.1371/journal.pone.0025861.t003
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by comparing growth in drug-containing wells with growth in
drug-free wells. [31] Reported advantages of MODS include the
reduced time to M. tuberculosis diagnosis including drug suscepti-
bility results and safety relative to other indirect susceptibility
testing methods. [33]
Xpert MTB/RIF uses an automated real-time polymerase-
chain-reaction to amplify and to detect a segment of the M.
tuberculosis specific rpoB gene; [32] this diagnostic test has been
shown to be more accurate than existing protocols for identifying
TB patients under field conditions in TB-endemic settings, and in
smear-negative patients is capable of significantly reducing the
time to appropriate treatment. [34] This test also identifies
rifampin resistance, a reasonable surrogate marker for MDR-TB.
Being able to more rapidly recognized MDR-TB patients has been
associated with substantial declines in time to appropriate therapy
for MDR-TB patients, [35] and may reduce transmission. [36]
The expanded use of this or similar tests may increase laboratory
costs for TB diagnosis. However, these tests may be cost-effective
overall if they improve diagnostic accuracy and reduce time to
inappropriate treatment. [37]
Study strengths include the use of DST in consecutive new TB
patients to identify MDR-TB cases. The high participation rate of
cases and TB controls in this study meant that they are likely
representative of new MDR-TB and drug-sensitive TB patients in
SJL. Cases and controls were drawn from the entire district, and
not limited to a single institution or referral center. The inclusion
of community controls enabled us to explore risk factors for MDR
disease separate from those for TB. Study limitations include the
lack of drug-susceptibility data for TB controls and the moderate
refusal rate among community controls. The lack of DST among
TB controls means that some MDR-TB patients may have been
misclassified as having drug-susceptible disease. [26] This
misclassification, if it occurred, would have had the effect of
reducing differences between the two groups. Except for a higher
level of education, community controls were similar to community
members who declined to participate in the study. Cases and
controls were similar across a range of socioeconomic indicators; it
seems unlikely that a lower community control refusal rate would
have substantially affected the findings.
Case-control studies are subject to recall bias and confounding.
Public health programs based on self-reported risk factors such as
selected DST are subject to the same risks of reporting errors and
misclassifications. Our results likely reflect what is achievable in
existing NTP DST screening programs. Confounding was
addressed in the multivariate models, though residual confounding
could exist.
This case-control study of self-reported MDR-TB risk factors in
the setting of an excellent NTP, low HIV co-infection rates and a
substantial burden of MDR disease suggests that the existing TB
control of sputum smears for diagnosis, standard treatment for
new TB cases and selected DST of high-risk groups identified
through self-reporting is insufficient to control MDR-TB once
established. DST screening in new TB patients will need to be
expanded if MDR-TB control is to be achieved in this setting.
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